spacer
home > ict > winter 2019 > redefining the gold standard
PUBLICATIONS
International Clinical Trials

Redefining the Gold Standard

Adaptive clinical trials have risen in popularity and gained more attention since the FDA Critical Path Initiative (2004) and Critical Path Opportunity List (2006) called for innovative solutions to transform the way medicinal products are developed, evaluated, and manufactured. They are now being commonly used to quickly predict the likelihood of the success or failure of a drug in early stages of drug development.

The release of the FDA’s draft guidance in 2010 on “adaptive design clinical trials for drugs and biologics” provided a suggested framework for designing such studies and for using them to make decisions that would allow the innovator to “fail early.” EMA’s Committee for Medicinal Products for Human Use released a similar draft in 2006 (1).

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
Dr Chitra Lele is Chief Scientific Officer at Sciformix, a Covance Company, with over 20 years of experience in the healthcare industry. She has been part of the company’s leadership from its inception and has been instrumental in establishing and growing the organisation. Prior to Sciformix, Chitra was Executive Director responsible for Indian operations of Pfizer Global R&D. With a PhD in statistics from Stanford University, US, her prior experience includes work as a biostatistician in cancer epidemiology at both Stanford and University of California, US.

Dr Ritu Budania is a Drug Safety Physician for global medical safety operations at Sciformix, a Covance Company. She completed her MBBS from Topiwala National Medical College, India, and MD Pharmacology from Government Medical College, India. Ritu has assisted in preparing ‘Desk View Clinical Trials in India’ for the WHO and prepared signal reports for Pharmacovigilance Programme of India (PvPI). She was in charge of the adverse drug monitoring centre under PvPI, at King Edward Memorial Hospital, India. Ritu has expertise in pharmacovigilance, clinical pharmacology, medical writing, clinical research, and clinical trials. She is also an experienced industry guest speaker in the subject of pharmacology.
Print this page
Send to a friend
Privacy statement
News and Press Releases

A new anti-tumour treatment is one step closer to the clinic thanks to a new collaboration between In3Bio and 3P Biopharmaceuticals

[Pamplona, November 26 2019] 3P Biopharmaceuticals, a leading Contract Development and Manufacturing Organization (CDMO) specialized in process development and cGMP manufacturing of biologics, has been chosen by In3Bio, a UK based Biotech company, to collaborate in the development of a novel anti-tumour treatment.
More info >>

White Papers

Blockbuster Drugs Need Blockbuster Components

West Pharmaceutical Services, Inc.

Many of the world’s blockbuster drugs are now delivered via a prefilled syringe system or auto-injector. To ensure patient safety, pharmaceutical manufacturers need high-quality components that feature reduced particulates and ensure consistency of delivery while fitting the changing needs of higher-volume delivery systems.
More info >>

 
Industry Events

Clinical Operations in Oncology Trials West Coast

17-18 November 2020, Hilton San Francisco Airport Bayfront

Clinical Operations in Oncology Trials West Coast will be returning this April for another 2 day event full of thought-provoking presentations, discussions and roundtables. This years' conference highlights include the high-level, interactive immuno-oncology discussion panel where specialists from Shasta Bio Ventures, Abbvie and BeiGene shared their top tips on how to run successful and impactful immuno-oncology studies.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement